Brainsway (NASDAQ:BWAY) Stock Rating Upgraded by Wall Street Zen

Brainsway (NASDAQ:BWAY) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Sunday.

A number of other analysts have also issued reports on the company. HC Wainwright raised their price target on Brainsway from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Northland Securities raised their target price on shares of Brainsway from $19.00 to $23.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 12th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Brainsway in a report on Monday, November 17th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Brainsway currently has an average rating of “Moderate Buy” and an average target price of $20.50.

Brainsway Stock Performance

Shares of BWAY opened at $15.02 on Friday. Brainsway has a 1 year low of $7.84 and a 1 year high of $17.92. The company’s 50 day simple moving average is $15.72 and its 200 day simple moving average is $13.59. The company has a market capitalization of $293.79 million, a price-to-earnings ratio of 50.07 and a beta of 1.22.

Brainsway (NASDAQ:BWAY) last issued its quarterly earnings results on Tuesday, November 11th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.03). Brainsway had a net margin of 12.73% and a return on equity of 9.46%. The business had revenue of $13.51 million during the quarter, compared to analyst estimates of $13.04 million. Brainsway has set its FY 2025 guidance at EPS. Equities analysts expect that Brainsway will post 0.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Brainsway

Several institutional investors have recently bought and sold shares of BWAY. Eagle Global Advisors LLC purchased a new position in shares of Brainsway in the 1st quarter valued at $590,000. UBS Group AG increased its holdings in Brainsway by 2,028.6% in the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock valued at $963,000 after purchasing an additional 60,877 shares in the last quarter. Two Sigma Investments LP raised its position in Brainsway by 25.2% in the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock valued at $1,551,000 after purchasing an additional 20,706 shares during the period. Y.D. More Investments Ltd acquired a new position in shares of Brainsway during the third quarter worth about $263,000. Finally, Millennium Management LLC boosted its position in shares of Brainsway by 69.6% in the third quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock worth $600,000 after buying an additional 16,354 shares during the period. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.